Recurrences of Atrial Fibrillation Despite Durable Pulmonary Vein Isolation: The PARTY-PVI Study.


Journal

Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3084
Titre abrégé: Circ Arrhythm Electrophysiol
Pays: United States
ID NLM: 101474365

Informations de publication

Date de publication:
03 2023
Historique:
pubmed: 22 2 2023
medline: 24 3 2023
entrez: 21 2 2023
Statut: ppublish

Résumé

Recurrences of atrial fibrillation (AF) after pulmonary vein isolation (PVI) are mainly due to pulmonary vein reconnection. However, a growing number of patients have AF recurrences despite durable PVI. The optimal ablative strategy for these patients is unknown. We analyzed the impact of current ablation strategies in a large multicenter study. Patients undergoing a redo ablation for AF and presenting durable PVI were included. The freedom from atrial arrhythmia after pulmonary vein-based, linear-based, electrogram-based, and trigger-based ablation strategies were compared. Between 2010 and 2020, 367 patients (67% men, 63±10 years, 44% paroxysmal) underwent a redo ablation for AF recurrences despite durable PVI at 39 centers. After durable PVI was confirmed, linear-based ablation was performed in 219 (60%) patients, electrogram-based ablation in 168 (45%) patients, trigger-based ablation in 101 (27%) patients, and pulmonary vein-based ablation in 56 (15%) patients. Seven patients (2%) did not undergo any additional ablation during the redo procedure. After 22±19 months of follow-up, 122 (33%) and 159 (43%) patients had a recurrence of atrial arrhythmia at 12 and 24 months, respectively. No significant difference in arrhythmia-free survival was observed between the different ablation strategies. Left atrial dilatation was the only independent factor associated with arrhythmia-free survival (HR, 1.59 [95% CI, 1.13-2.23]; In patients with recurrent AF despite durable PVI, no ablation strategy used alone or in combination during the redo procedure appears to be superior in improving arrhythmia-free survival. Left atrial size is a significant predictor of ablation outcome in this population.

Sections du résumé

BACKGROUND
Recurrences of atrial fibrillation (AF) after pulmonary vein isolation (PVI) are mainly due to pulmonary vein reconnection. However, a growing number of patients have AF recurrences despite durable PVI. The optimal ablative strategy for these patients is unknown. We analyzed the impact of current ablation strategies in a large multicenter study.
METHODS
Patients undergoing a redo ablation for AF and presenting durable PVI were included. The freedom from atrial arrhythmia after pulmonary vein-based, linear-based, electrogram-based, and trigger-based ablation strategies were compared.
RESULTS
Between 2010 and 2020, 367 patients (67% men, 63±10 years, 44% paroxysmal) underwent a redo ablation for AF recurrences despite durable PVI at 39 centers. After durable PVI was confirmed, linear-based ablation was performed in 219 (60%) patients, electrogram-based ablation in 168 (45%) patients, trigger-based ablation in 101 (27%) patients, and pulmonary vein-based ablation in 56 (15%) patients. Seven patients (2%) did not undergo any additional ablation during the redo procedure. After 22±19 months of follow-up, 122 (33%) and 159 (43%) patients had a recurrence of atrial arrhythmia at 12 and 24 months, respectively. No significant difference in arrhythmia-free survival was observed between the different ablation strategies. Left atrial dilatation was the only independent factor associated with arrhythmia-free survival (HR, 1.59 [95% CI, 1.13-2.23];
CONCLUSIONS
In patients with recurrent AF despite durable PVI, no ablation strategy used alone or in combination during the redo procedure appears to be superior in improving arrhythmia-free survival. Left atrial size is a significant predictor of ablation outcome in this population.

Identifiants

pubmed: 36802906
doi: 10.1161/CIRCEP.122.011354
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e011354

Auteurs

Karim Benali (K)

CHU Saint Etienne, University of Rennes, INSERM, LTSI -UMR 1099, Rennes (K.B.).

Valentin Barré (V)

University of Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes (V.B., V.G., D.P., R.P.M.).

Vincent Galand (V)

University of Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes (V.B., V.G., D.P., R.P.M.).

Antoine Milhem (A)

CH La Rochelle (A.M.).

Séverine Philibert (S)

Hôpital Européen Georges Pompidou, Paris (S.P.).

Serge Boveda (S)

Cardiology-Heart Rhythm Management Department, Clinique Pasteur, Toulouse (S.B.).

Clément Bars (C)

Clinique Saint-Joseph, Marseille (C.B.).

Baptiste Maille (B)

CHU Marseille (B.M.).

Clémentine André (C)

CHU Bordeaux (C.A.).

Albin Behaghel (A)

Clinique Saint-Joseph, Trelazé (A.B.).

Ghassan Moubarak (G)

Clinique Ambroise Paré, Neuilly-Sur-Seine, Paris (G.M.).

Antoine Da Costa (A)

CHU Saint Etienne (A.D.C.).

Sandrine Venier (S)

CHU Grenoble (S.V.).

Frédéric Sebag (F)

Rythmologie, Institut Mutualiste Montsouris, Paris (F.S.).

Laurence Jésel-Morel (L)

CHU Strasbourg (L.J.-M.).

Duc Dang (D)

CH Aix-en-Provence (D.D.).

Benoit Guy-Moyat (B)

CHU Limoges (B.G.-M.).

Selim Abbey (S)

Hôpital Privé du Confluent, Nantes (S.A.).

Olivier Césari (O)

Clinique Saint-Augustin, Bordeaux (O.C.).

Nicolas Badenco (N)

Hôpital Pitié Salpêtrière, IHU ICAN, Paris (N.B.).

Antoine Lepillier (A)

Centre Cardiologique du Nord, Saint-Denis (A.L.).

Stéphane Boulé (S)

Hôpital Privé Le Bois, Lille (S.B.).

Vincent Algalarrondo (V)

Hôpital Bichat, Unité de Rythmologie, Paris (V.A.).

Babé Bakouboula (B)

Institut Cardiovasculaire de Strasbourg, Clinique RHENA (B.B.).

Jacques Mansourati (J)

CHU Brest (J.M.).

Philippe Lagrange (P)

Clinique St Pierre, Perpignan (P.L.).

Abdeslam Bouzeman (A)

Hôpital Privé de Parly 2, Le Chesnay-Rocquencourt (A.B.).

Agustin Bortone (A)

ELSAN Hôpital Privé Les Franciscaines, Nîmes (A.B.).

Sok-Sithikun Bun (SS)

CHU Nice, France (S.-S.B.).

Dominique Pavin (D)

University of Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes (V.B., V.G., D.P., R.P.M.).

Laurent Macle (L)

Department of Medicine, Electrophysiology Service at the Montreal Heart Institute, Canada (L.M.).

Raphaël P Martins (RP)

University of Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes (V.B., V.G., D.P., R.P.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH